In patients with asymptomatic aortic valve stenosis, metoprolol increased systolic ejection time and reduced aortic valve gradients, global afterload, and myocardial oxygen requirements (P<0.01).
RCT
Does metoprolol reduce hemodynamic and metabolic burden in patients with asymptomatic aortic valve stenosis?
Metoprolol demonstrates favorable hemodynamic and metabolic effects in asymptomatic aortic stenosis, potentially offering a novel pharmacological strategy to delay disease progression.
p-value: p=<0.01
BACKGROUND: Currently, no pharmacological treatment can modify the natural history of aortic valve stenosis (AS). This underlines the critical need to explore novel treatment strategies, which could postpone or prevent the need for aortic valve replacement in patients with asymptomatic AS. The objectives of this study were to investigate whether metoprolol reduce the hemodynamic and metabolic burden imposed by AS. METHODS AND RESULTS: <0.01). There were 2 adverse cardiovascular events in the metoprolol group and none in the placebo group. CONCLUSIONS: In patients with asymptomatic AS, metoprolol increases systolic ejection time and reduces aortic valve gradients, global afterload, and myocardial oxygen requirements. Thus, metoprolol displays favorable hemodynamic and metabolic effects and could improve outcome in patients with asymptomatic AS. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02076711.
Hansson et al. (Thu,) conducted a rct in asymptomatic aortic valve stenosis. metoprolol vs. placebo was evaluated on hemodynamic and metabolic burden (p=<0.01). In patients with asymptomatic aortic valve stenosis, metoprolol increased systolic ejection time and reduced aortic valve gradients, global afterload, and myocardial oxygen requirements (P<0.01).